Alba Mota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alba Mota has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Gema Moreno-Bueno
Fundación MD Anderson Internacional, Madrid, Spain
8 shared publications - Alejandro Rojo-Sebastián
University of Texas MD Anderson Cancer Center
4 shared publications Xavier Matias-Guiu
Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain
4 shared publications- Joaquín Arribas
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
3 shared publications - Alicia García Arroyo
Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
2 shared publications Amparo Cano
Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain
2 shared publications
Latest Publications
- 1 January 2017
- Published by Elsevier in Laboratory Investigation
- Vol. 30 (1) , 134-145
Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
- 1 January 2017
- Published by Elsevier in Laboratory Investigation
- Vol. 30 (1) , 134-145
Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
- Open Access
- 1 August 2016
- Published by Elsevier in EBioMedicine
- Vol. 10, 137-149
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies
- 1 August 2016
- Published by Elsevier in EBioMedicine
- Vol. 10, 137-149
Open AccessPremalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies
- Open Access
- 22 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (35) , 56295-56308
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
- 22 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (35) , 56295-56308
Open AccessGasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
- 1 June 2016
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. Publish Ah
Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma
- 1 June 2016
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. Publish Ah
Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma
- Open Access
- 30 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
High grade serous ovarian cancer is characterised by high initial response to chemotherapy but poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated with p53 accumulation. TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift or splice-site mutations associated to complete absence of p53 expression. Different studies show that this kind of tumors may have a worse prognosis than other TP53 mutated HGSC. In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome sequencing and comparative genome hybridisation. Significant heterogeneity was found among the different tumor samples, both at the mutational and copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples. Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1. Using functional annotation and network analysis, we identified those biological functions most significantly altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid metabolism emerged as important for tumor development and progression, suggesting its potential interest as therapeutic targets. Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the most aggressive subpopulations and at least some of the genes that may be implicated in its progression and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover possible therapeutic strategies.
- 30 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Open AccessIntra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
High grade serous ovarian cancer is characterised by high initial response to chemotherapy but poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated with p53 accumulation. TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift or splice-site mutations associated to complete absence of p53 expression. Different studies show that this kind of tumors may have a worse prognosis than other TP53 mutated HGSC. In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome sequencing and comparative genome hybridisation. Significant heterogeneity was found among the different tumor samples, both at the mutational and copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples. Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1. Using functional annotation and network analysis, we identified those biological functions most significantly altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid metabolism emerged as important for tumor development and progression, suggesting its potential interest as therapeutic targets. Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the most aggressive subpopulations and at least some of the genes that may be implicated in its progression and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover possible therapeutic strategies.
- 1 November 2015
- Published by Elsevier in Laboratory Investigation
- Vol. 28 (11) , 1492-1503
A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer
- 1 November 2015
- Published by Elsevier in Laboratory Investigation
- Vol. 28 (11) , 1492-1503
A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer
- 1 August 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 286 (3) , 168-177
α-Hispanolol sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis via death receptor up-regulation
- 1 August 2015
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 286 (3) , 168-177
α-Hispanolol sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis via death receptor up-regulation
- 1 December 2014
- Published by Elsevier in Human Pathology
- Vol. 45 (12) , 2394-2403
A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry
- 1 December 2014
- Published by Elsevier in Human Pathology
- Vol. 45 (12) , 2394-2403
A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry
- Open Access
- 27 March 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3) , e90099
Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells
Gasdermin B (GSDMB) belongs to the Gasdermin protein family that comprises four members (GSDMA-D). Gasdermin B expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-expression has been related to tumor progression. At least four splicing isoforms of GSDMB have been identified, which may play differential roles in cancer. However, the implication of GSDMB in carcinogenesis and tumor progression is not well understood. Here, we uncover for the first time the functional implication of GSDMB in breast cancer. Our data shows that high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients included in an expression dataset (>1,000 cases). We demonstrate that GSDMB is upregulated in breast carcinomas compared to normal breast tissue, being the isoform 2 (GSDMB-2) the most differentially expressed. In order to evaluate the functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2). The overexpression of both isoforms in the MCF7 breast carcinoma cell line promotes cell motility and invasion, while its silencing in HCC1954 breast carcinoma cells decreases the migratory and invasive phenotype. Importantly, we demonstrate that both isoforms have a differential role on the activation of Rac-1 and Cdc-42 Rho-GTPases. Moreover, our data support that GSMDB-2 induces a pro-tumorigenic and pro-metastatic behavior in mouse xenograft models as compared to GSDMB-1. Finally, we observed that although both GSDMB isoforms interact in vitro with the chaperone Hsp90, only the GSDMB-2 isoform relies on this chaperone for its stability. Taken together, our results provide for the first time evidences that GSDMB-2 induces invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic marker in breast cancer.
- 27 March 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3) , e90099
Open AccessGasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells
Gasdermin B (GSDMB) belongs to the Gasdermin protein family that comprises four members (GSDMA-D). Gasdermin B expression has been detected in some tumor types such as hepatocarcinomas, gastric and cervix cancers; and its over-expression has been related to tumor progression. At least four splicing isoforms of GSDMB have been identified, which may play differential roles in cancer. However, the implication of GSDMB in carcinogenesis and tumor progression is not well understood. Here, we uncover for the first time the functional implication of GSDMB in breast cancer. Our data shows that high levels of GSDMB expression is correlated with reduced survival and increased metastasis in breast cancer patients included in an expression dataset (>1,000 cases). We demonstrate that GSDMB is upregulated in breast carcinomas compared to normal breast tissue, being the isoform 2 (GSDMB-2) the most differentially expressed. In order to evaluate the functional role of GSDMB in breast cancer two GSDMB isoforms were studied (GSDMB-1 and GSDMB-2). The overexpression of both isoforms in the MCF7 breast carcinoma cell line promotes cell motility and invasion, while its silencing in HCC1954 breast carcinoma cells decreases the migratory and invasive phenotype. Importantly, we demonstrate that both isoforms have a differential role on the activation of Rac-1 and Cdc-42 Rho-GTPases. Moreover, our data support that GSMDB-2 induces a pro-tumorigenic and pro-metastatic behavior in mouse xenograft models as compared to GSDMB-1. Finally, we observed that although both GSDMB isoforms interact in vitro with the chaperone Hsp90, only the GSDMB-2 isoform relies on this chaperone for its stability. Taken together, our results provide for the first time evidences that GSDMB-2 induces invasion, tumor progression and metastasis in MCF7 cells and that GSDMB can be considered as a new potential prognostic marker in breast cancer.
- Open Access
- 2 August 2012
- Published by Wiley in The FASEB Journal
- Vol. 26 (11) , 4481-4494
The protease MT1‐MMP drives a combinatorial proteolytic program in activated endothelial cells
The mechanism by which proteolytic events translate into biological responses is not well understood. To explore the link of pericellular proteolysis to events relevant to capillary sprouting within the inflammatory context, we aimed at the identification of the collection of substrates of the protease MT1‐MMP in endothelial tip cells induced by inflammatory stimuli. We applied quantitative proteomics to endothelial cells (ECs) derived from wild‐type and MT1‐MMP‐null mice to identify the substrate repertoire of this protease in TNF‐α‐activated ECs. Bioinformatics analysis revealed a combinatorial MT1‐MMP proteolytic program, in which combined rather than single substrate processing would determine biological decisions by activated ECs, including chemotaxis, cell motility and adhesion, and vasculature development. MT1‐MMP‐deficient ECs inefficiently processed several of these substrates (TSP1, CYR61, NID1, and SEM3C), validating the model. This novel concept of MT1‐MMP‐driven combinatorial proteolysis in angiogenesis might be extendable to proteolytic actions in other cellular contexts.—Koziol, A., Gonzalo, P., Mota, A., Pollán, Á., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., Arribas, J., Canals, F., Arroyo, A. G. The protease MT1‐MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 26, 4481–4494 (2012). www.fasebj.org
- 2 August 2012
- Published by Wiley in The FASEB Journal
- Vol. 26 (11) , 4481-4494
Open AccessThe protease MT1‐MMP drives a combinatorial proteolytic program in activated endothelial cells
The mechanism by which proteolytic events translate into biological responses is not well understood. To explore the link of pericellular proteolysis to events relevant to capillary sprouting within the inflammatory context, we aimed at the identification of the collection of substrates of the protease MT1‐MMP in endothelial tip cells induced by inflammatory stimuli. We applied quantitative proteomics to endothelial cells (ECs) derived from wild‐type and MT1‐MMP‐null mice to identify the substrate repertoire of this protease in TNF‐α‐activated ECs. Bioinformatics analysis revealed a combinatorial MT1‐MMP proteolytic program, in which combined rather than single substrate processing would determine biological decisions by activated ECs, including chemotaxis, cell motility and adhesion, and vasculature development. MT1‐MMP‐deficient ECs inefficiently processed several of these substrates (TSP1, CYR61, NID1, and SEM3C), validating the model. This novel concept of MT1‐MMP‐driven combinatorial proteolysis in angiogenesis might be extendable to proteolytic actions in other cellular contexts.—Koziol, A., Gonzalo, P., Mota, A., Pollán, Á., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., Arribas, J., Canals, F., Arroyo, A. G. The protease MT1‐MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 26, 4481–4494 (2012). www.fasebj.org